Exelixis Inc
Contact Information
Company Details
Location Type: Branch
Industry: Biological Products, Except Diagnostic Substances
Ownership: Public
Year Founded: 1994
Sales Range: $1,000,000,000 to $4,999,999,999
Employees: 1,000 to 2,000
Is This Your Customer, Supplier, Or Partner?
Is This Your Business?
Is This Your Customer, Supplier, Or Partner?
Pull Their Credit Report CREATE A FREE ACCOUNT
Company Credit Alerts
Recent Alerts
Credit Risk Increase
No
Overall Payments
No
Bankruptcy
No
Tax Liens
No
UCC Filings
No
See All Credit Alerts On Your Customers From The Past 12 Months
Company Payment Insights
Risk of Severe Delinquency
See this company's likelihood of paying its bills in a severely delinquent manner (90+ days late) in the next 12 months.
Company News
Latest News
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX (cabozantinib) Tablets
Business Wire Health News
Jan 18 2024
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
Bio Space - All News
Jan 12 2024
Exelixis inks licensing deal with Insilico for tumor candidate
Seeking Alpha Latest
Sep 12 2023
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
BusinessWire Science News
Aug 23 2023
Exelixis, Inc. Announces Settlement of CABOMETYX (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceutical
Business Wire Professional Services News
Jul 23 2023
Analyze Your Entire AR Portfolio with One Free Credit Tool
LEARN MORECompany Buying Behavior
Overall Company Spend
Company Spend by Category
Material Spend
ONE YEAR GROWTH
Operations Spend
ONE YEAR GROWTH
Shipping Spend
ONE YEAR GROWTH
See this company's YOY change in purchases for each major spend category and learn the business implications of those changes.
BUY CREDIT REPORTCredit Analysis Tip
Purchases of key products and services provides insight into whether a business is growing or declining financially. Analyzing spending enables creditors predict risk scenarios before other credit analysis methods. Lean how in our latest case study.
DOWNLOAD CASE STUDYCompany Credit Alerts
Recent Alerts
Credit Risk Increase
No
Overall Payments
No
Bankruptcy
No
Tax Liens
No
UCC Filings
No
See All Credit Alerts On Your Customers From The Past 12 Months
Sales Insights
More Businesses Like this
Discover other companies in the same industry you can sell to: